| 47.41 Data as of May 20 |  -0.12 / -0.25%Today’s Change | 39.62 Today|||52-Week Range 59.24 | -7.33% Year-to-Date |
| Bayer's Xofigo Cleared in the US - Analyst Blog May 16 / Zacks.com | Medivation Loss Narrower Than Expected - Analyst Blog May 13 / Zacks.com |
| Previous close | 47.53 |
| Today’s open | 47.64 |
| Day’s range | 47.25 - 48.84 |
| Volume | 1,107,705 |
| Average volume (3 months) | 1,250,893 |
| Market cap | $3.6B |
| Dividend yield | -- |
| Earnings growth (last year) | -0.90% |
| Earnings growth (this year) | -71.73% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +200.88% |
| P/E ratio | NM |
| Price/Sales | 20.69 |
| Price/Book | 48.26 |
| Today’s change | Today’s % change | |
|---|---|---|
| SLXPSalix Pharmaceutical... | -0.53 | -0.89% |
| UTHRUnited Therapeutics ... | -1.06 | -1.53% |
| JAZZJazz Pharmaceuticals... | +0.13 | +0.22% |
| ENDPEndo Health Solution... | -0.65 | -1.89% |
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $181.7M |
| Annual profit (last year) | -$41.3M |
| Net profit margin | -22.71% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director David T. Hung, MD |
Secretary, Chief Financial & Business Officer Clarence Patrick Machado |
Corporate headquarters San Francisco, California |
.
